Review of P-gp Inhibition Data in Recently Approved New Drug Applications: Utility of the Proposed [I1]/IC50 and [I2]/IC50 Criteria in the P-gp Decision Tree

被引：45

作者：

Agarwal, Sheetal ^{[1
]}

Arya, Vikram ^{[1
]}

Zhang, Lei ^{[1
]}

机构：

[1] US FDA, Silver Spring, MD 20993 USA

来源：

JOURNAL OF CLINICAL PHARMACOLOGY | 2013年 / 53卷 / 02期

关键词：

I1; IC50 and [I2; IC50; criteria; P-gp decision tree; digoxin; IN-VITRO; TRANSPORTERS; GLYCOPROTEIN; DIGOXIN;

D O I：

10.1177/0091270011436344

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：228 / 233

页数：6

共 20 条

[1]

[Anonymous], TASIGNA NILOTINIB CL

[2]

[Anonymous], 2011, TYKERB LAPATINIB PAC

[3]

[Anonymous], INTELENCE ETRAVIRINE

[4]

[Anonymous], 2007, TYKERB LAPATINIB PAC

[5]

[Anonymous], 2010, NEXAVAR SORAFENIB PA

[6]

[Anonymous], TYKERB LAPATINIB APP

[7]

[Anonymous], SELZENTRY MARAVIROC

[8]

[Anonymous], 2007, TASIGNA NILOTINIB PA

[9] Refining the In Vitro and In Vivo Critical Parameters for P-Glycoprotein, [I]/IC50 and [I2]/IC50, That Allow for the Exclusion of Drug Candidates from Clinical Digoxin Interaction Studies [J].

Cook, Jack A. ;

Feng, Bo ;

Fenner, Katherine S. ;

Kempshall, Sarah ;

Liu, Ray ;

Rotter, Charles ;

Smith, Dennis A. ;

Troutman, Matthew D. ;

Ullah, Mohammed ;

Lee, Caroline A. .

MOLECULAR PHARMACEUTICS, 2010, 7 (02) :398-411

[10] The Utility of In Vitro Data in Making Accurate Predictions of Human P-Glycoprotein-Mediated Drug-Drug Interactions: A Case Study for AZD5672 [J].

Elsby, Robert ;

Gillen, Michael ;

Butters, Caroline ;

Imisson, Gemma ;

Sharma, Pradeep ;

Smith, Veronica ;

Surry, Dominic D. .

DRUG METABOLISM AND DISPOSITION, 2011, 39 (02) :275-282

← 1 2 →